Arrowstreet Capital Limited Partnership Buys 432,498 Shares of Stryker Corporation $SYK

Arrowstreet Capital Limited Partnership raised its stake in Stryker Corporation (NYSE:SYK) by 1,925.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 454,965 shares of the medical technology company’s stock after purchasing an additional 432,498 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Stryker were worth $159,907,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker during the fourth quarter valued at approximately $27,000. DJE Kapital AG bought a new position in shares of Stryker during the fourth quarter valued at approximately $28,000. Finally, CGC Financial Services LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $29,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Stryker Trading Down 1.4%

NYSE SYK opened at $307.86 on Tuesday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The stock has a market cap of $118.02 billion, a P/E ratio of 35.63, a P/E/G ratio of 1.97 and a beta of 0.78. The stock’s fifty day moving average price is $315.93 and its 200-day moving average price is $343.32. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the company posted $2.84 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Analysts Set New Price Targets

A number of brokerages recently commented on SYK. Truist Financial restated a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a report on Monday, May 4th. William Blair restated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Canaccord Genuity Group decreased their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Evercore set a $355.00 price target on Stryker in a research note on Friday, May 1st. Finally, Leerink Partners reduced their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.